Literature DB >> 7590756

Study of the association of HLA class I antigens with kala-azar.

Z Faghiri1, S Z Tabei, F Taheri.   

Abstract

HLA class I antigen frequencies were studied in 52 patients with kala-azar and compared with 222 unrelated healthy controls. The relative risk (RR) and etiologic or preventive fraction (EF/PF) were determined for each character, and statistical significance was evaluated with chi 2 with Yates' correction. Results showed that the only antigen with a statistically significant difference was HLA-A26 (15.38 vs. 1.35%; p = 0.004), with RR = 13.27 and EF = 0.142. This indicates a high risk of contracting the disease for HLA-A26-positive individuals and a relatively remarkable influence of this antigen on the prevalence rate of kala-azar.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590756     DOI: 10.1159/000154309

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  9 in total

1.  The relationship between human leukocyte antigens (HLA) and renal cell carcinoma.

Authors:  Erkan Yilmaz; Arman Çekmen; Emre Akkuş; Bülent Önal; Ali Uğur Özalp; Vural Solok; Ergun Erdoğan; Bülent Eren
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

2.  Susceptibility to visceral leishmaniasis in the domestic dog is associated with MHC class II polymorphism.

Authors:  Rupert J Quinnell; Lorna J Kennedy; Annette Barnes; Orin Courtenay; Christopher Dye; Lourdes M Garcez; Marie-Anne Shaw; Stuart D Carter; Wendy Thomson; William E R Ollier
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

3.  Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.

Authors:  S M B Jeronimo; A K B Holst; S E Jamieson; R Francis; D R A Martins; F L Bezerra; N A Ettinger; E T Nascimento; G R Monteiro; H G Lacerda; E N Miller; H J Cordell; P Duggal; T H Beaty; J M Blackwell; M E Wilson
Journal:  Genes Immun       Date:  2007-08-23       Impact factor: 2.676

Review 4.  Genetics and visceral leishmaniasis: of mice and man.

Authors:  J M Blackwell; M Fakiola; M E Ibrahim; S E Jamieson; S B Jeronimo; E N Miller; A Mishra; H S Mohamed; C S Peacock; M Raju; S Sundar; M E Wilson
Journal:  Parasite Immunol       Date:  2009-05       Impact factor: 2.280

5.  Genetic control of canine leishmaniasis: genome-wide association study and genomic selection analysis.

Authors:  Javier Quilez; Verónica Martínez; John A Woolliams; Armand Sanchez; Ricardo Pong-Wong; Lorna J Kennedy; Rupert J Quinnell; William E R Ollier; Xavier Roura; Lluís Ferrer; Laura Altet; Olga Francino
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 6.  Infectious diseases and immunity: special reference to major histocompatibility complex.

Authors:  N Singh; S Agrawal; A K Rastogi
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

Review 7.  Association of HLA class I and II genes with cutaneous leishmaniasis: a case control study from Sri Lanka and a systematic review.

Authors:  Nilakshi Samaranayake; Sumadhya D Fernando; Nilaksha F Neththikumara; Chaturaka Rodrigo; Nadira D Karunaweera; Vajira H W Dissanayake
Journal:  BMC Infect Dis       Date:  2016-06-14       Impact factor: 3.090

8.  An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Authors:  Md Anik Ashfaq Khan; Jenifar Quaiyum Ami; Khaledul Faisal; Rajashree Chowdhury; Prakash Ghosh; Faria Hossain; Ahmed Abd El Wahed; Dinesh Mondal
Journal:  Parasit Vectors       Date:  2020-04-15       Impact factor: 3.876

9.  HLA-DRB1 Alleles Associated with Lower Leishmaniasis Susceptibility Share Common Amino Acid Polymorphisms and Epitope Binding Repertoires.

Authors:  Nicky de Vrij; Pieter Meysman; Sofie Gielis; Wim Adriaensen; Kris Laukens; Bart Cuypers
Journal:  Vaccines (Basel)       Date:  2021-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.